(1RS,2RS)-2-hydroxy-1-cyclopentanecarboxamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1RS,2RS)-2-hydroxy-1-cyclopentanecarboxamide
• 英文别名: (+/-)-trans-2-hydroxycyclopentanecarboxamide；trans-2-hydroxy-1-cyclopentanecarboxamide；trans(1S*,2S*)-2-hydroxy-1-cyclopentanecarboxamide；(1S,2S)-2-hydroxycyclopentane-1-carboxamide
• 化学式: C₆H₁₁NO₂
• 分子量: 129.159
• InChiKey: XLPNKXDLOYEHIM-WHFBIAKZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1RS,2RS)-2-hydroxy-1-cyclopentanecarboxamide 在 lithium aluminium tetrahydride 、 sodium hydride 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 40.0h， 生成 (+/-)-trans-perhydrocyclopenta-1,3-oxazin-2-one
  参考文献：
  名称：

  Bioreduction of 2-oxocyclopentanecarboxamides: syntheses of optically active 2-aminomethyl- and 2-aminocyclopentanols

  摘要：

  The fungus Mortierella isabellina NRRL 1757 catalyzes the reduction of 2-oxocyclopentanecarboxamides with very high enantioselectivity giving, in most cases, the corresponding enantiopure 2-hydroxycyclopentanecarboxamides. The presence or absence of a substituent on the amidic nitrogen has a strong influence on the diastereoselectivity achieved in these processes. Optically active hydroxyamides prepared in these microbial reductions are used as starting materials for the preparation of optically active 2-aminomethyl- and 2-aminocyclopentanols. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(99)00016-6
• 作为产物：
  描述：

  2-aminocarbonylcyclopentanone 以 乙醇 为溶剂， 反应 96.0h， 以51%的产率得到(1RS,2RS)-2-hydroxy-1-cyclopentanecarboxamide
  参考文献：
  名称：

  Bioreduction of 2-oxocyclopentanecarboxamides: syntheses of optically active 2-aminomethyl- and 2-aminocyclopentanols

  摘要：

  The fungus Mortierella isabellina NRRL 1757 catalyzes the reduction of 2-oxocyclopentanecarboxamides with very high enantioselectivity giving, in most cases, the corresponding enantiopure 2-hydroxycyclopentanecarboxamides. The presence or absence of a substituent on the amidic nitrogen has a strong influence on the diastereoselectivity achieved in these processes. Optically active hydroxyamides prepared in these microbial reductions are used as starting materials for the preparation of optically active 2-aminomethyl- and 2-aminocyclopentanols. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(99)00016-6

文献信息

• [EN] ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS<br/>[FR] DÉRIVÉS D'ISOXAZOLE-THIAZOLE COMME AGONISTES INVERSES DU RÉCEPTEUR GABA A, UTILES DANS LE TRAITEMENT DE TROUBLES COGNITIFS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010127974A1

  公开（公告）日：2010-11-11

  The present invention is concerned with isoxazole-thiazole derivatives of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful as cognitive enhancer or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease.

  本发明涉及式I的异恶唑-噻唑衍生物，具有对GABA A α5受体的亲和力和选择性，其制备、含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物可用作认知增强剂或用于治疗和/或预防认知障碍，如阿尔茨海默病。
• Kinase inhibitor compounds
  申请人：Liang Congxin

  公开号：US20090076005A1

  公开（公告）日：2009-03-19

  The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes.

  这项发明涉及化合物、包含这些化合物的组合物，以及使用这些化合物和化合物组合物的方法。本文描述的化合物、组合物和方法可用于治疗激酶介导的过程，并治疗疾病和疾病症状，特别是那些由特定激酶酶介导的症状。
• QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS
  申请人：Knust Henner

  公开号：US20100125078A1

  公开（公告）日：2010-05-20

  The present invention relates to a compounds of formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , and n are as defined herein and to a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本发明涉及一种具有以下式I的化合物 其中 R 1 ，R 2 ，R 3 ，R 4 ，R 5 和n如本文所定义，并且涉及其药用活性盐，外消旋混合物，对映体，光学异构体或其互变异构体形式。本化合物是治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑症和注意力缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。
• TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS
  申请人：Dillon Michael Patrick

  公开号：US20150191487A1

  公开（公告）日：2015-07-09

  Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R 1 is optionally substituted tetrazolyl, R 2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R 3 , R 4 , R 5 and R 6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X 3 and/or a P2X 2/3 receptor antagonist and methods of making the compounds.

  化合物的化学式I：或其药用可接受的盐，其中，R1是可选的取代的四氮唑基，R2是可选的取代的苯基，可选的取代的吡啶基或可选的取代的噻吩基，而R3、R4、R5和R6如本文所定义。还提供了使用这些化合物治疗与P2X3和/或P2X2/3受体拮抗剂相关的疾病的方法，以及制备这些化合物的方法。
• Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists
  申请人：Dillon Patrick Michael

  公开号：US20080004442A1

  公开（公告）日：2008-01-03

  Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R 1 is optionally substituted tetrazolyl, R 2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R 3 , R 4 , R 5 and R 6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X 3 and/or a P2X 2/3 receptor antagonist and methods of making the compounds.

  公式I的化合物：或其药用盐，其中，R1是可选取代的四唑基，R2是可选取代的苯基，可选取代的吡啶基或可选取代的噻吩基，而R3、R4、R5和R6如本文所定义。还提供了使用这些化合物治疗与P2X3和/或P2X2/3受体拮抗剂相关的疾病的方法，以及制备这些化合物的方法。